

Rozanolixizumab approved to treat adult patients with the autoimmune disease generalised myasthenia gravis

The Medicines and Healthcare products Regulatory Agency (MHRA) has today (7 March 2024) approved the medicine rozanolixizumab (Rystiggo) to treat adults with generalised myasthenia gravis, an autoimmune disease that causes m...